|
Characteristics
|
whole period
|
phase A
|
phase B
|
phase C
|
phase D
|
p value
|
|---|
|
sex
|
|
female
|
52
|
16
|
12
|
17
|
7
|
0.059
|
|
male
|
72
|
20
|
6
|
26
|
20
| |
|
age (years)
|
15–75 (52.0)
|
25–73 (56.5)
|
19–71 (46.5)
|
18–75 (51)
|
15–70 (52)
|
0.763
|
|
> median(53–75)
|
59
|
19
|
8
|
19
|
13
|
0.890
|
|
< median(15–52)
|
65
|
17
|
10
|
24
|
14
| |
|
neutropenia (days)
|
12–179 (61)
|
15–150 (65.5)
|
12–168 (57.0)
|
18–122 (58.0)
|
12–179 (53.0)
|
0.520
|
|
> median(62–179)
|
60
|
22
|
8
|
19
|
11
|
0.342
|
|
< median(12–61)
|
64
|
14
|
10
|
24
|
16
| |
|
lineage
|
|
AML
|
102
|
31
|
15
|
33
|
23
|
0.729
|
|
ALL
|
22
|
5
|
3
|
10
|
4
| |
|
prophylaxis
|
|
FLCZ only
|
69
|
22
|
14
|
22
|
11
|
0.082
|
|
mold-active agent
|
55
|
14
|
4
|
21
|
16
| |
|
ITCZ
|
6
|
3
|
0
|
1
|
2
| |
|
VRCZ
|
5
|
1
|
1
|
1
|
2
| |
|
MCFG
|
50
|
12
|
3
|
21
|
14
| |
|
CPFG
|
1
|
0
|
0
|
0
|
1
| |
|
AMB
|
1
|
1
|
0
|
0
|
0
| |
|
L-AMB
|
5
|
0
|
1
|
3
|
1
| |
|
treatment response after induction chemotherapy
|
|
CR
|
76
|
21
|
11
|
24
|
20
|
0.677
|
|
CRi
|
3
|
1
|
1
|
1
|
0
| |
|
non-CR
|
45
|
14
|
6
|
18
|
7
| |
|
median follow-up of event free survivors (days)
|
139.0 (27–330)
|
132.5 (29–236)
|
149.0 (27–330)
|
139.0 (42–261)
|
135.0 (41–272)
|
0.963
|
- Note. AML denotes acute myelogenous leukemia; ALL acute lymphoblastic leukemia, FLCZ fluconazole, ITCZ itraconazole, VRCZ voriconazole, MCFG micafungin, CPFG caspofungin, AMB amphotericin b, L-AMB liposomal amphotericin b, CR complete remission, CRi complete remission with incomplete hematologic recovery
